Sandoz plans to build a Biosimilar Technical Development Center in Slovenia
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Advances clinical research capabilities with leading regulatory grade registries platform
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Dr. Vivek joins Healthium after a stint at Ethicon, Johnson & Johnson
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
Subscribe To Our Newsletter & Stay Updated